Stockscreener 앱 받기
4.78
8.64%
0.38
시간 외 거래:
4.83
0.05
+1.05%
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
Yu-Waye Chu Sells 21,279 Shares of CytomX Therapeutics (NASDAQ:CTMX) Stock - MarketBeat
Sean Mccarthy Sells 118,969 Shares of CytomX Therapeutics (NASDAQ:CTMX) Stock - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) CFO Sells $124,053.66 in Stock - MarketBeat
Insider Selling: CytomX Therapeutics (NASDAQ:CTMX) SVP Sells 31,492 Shares of Stock - MarketBeat
CytomX (CTMX) CMO sells 21,279 shares to cover RSU tax obligations - Stock Titan
CytomX Therapeutics SVP Belvin sells $202k in stock - Investing.com
CytomX Therapeutics (CTMX) CEO sells shares to cover RSU tax obligations - Stock Titan
Tax-driven share sale by CytomX (CTMX) chief scientist on RSU vesting - Stock Titan
CytomX (NASDAQ: CTMX) CFO sells 19,323 shares for tax withholding - Stock Titan
CytomX Therapeutics Raises $234 Million in Equity Offering - TipRanks
CytomX prices $5.30 public offering to raise ~$234.4M; includes pre-funded warrants - TradingView
CytomX (NASDAQ: CTMX) prices $234.4M stock and pre-funded warrant deal - Stock Titan
CytomX Therapeutics (NASDAQ:CTMX) Given New $16.00 Price Target at Barclays - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Shares Gap Up After Analyst Upgrade - MarketBeat
CTMX Sees Price Target Raised to $16 by Jefferies Today | CTMX S - GuruFocus
Jefferies Maintains Buy on CTMX (CytomX Therapeutics) March 18, 2026 - Meyka
Latham Watkins Advises CytomX Therapeutics on Offering of Common Stock Pre Funded Warrants - Latham & Watkins LLP
CytomX (NASDAQ: CTMX) offers 45.99M shares and 1.18M pre‑funded warrants - Stock Titan
CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside - Stocktwits
Why Is CytomX Therapeutics Stock Falling On Wednesday? - Benzinga
CytomX Stocks Slide Amidst Profit Woes and Revenue Shortfall - timothysykes.com
CytomX Therapeutics (CTMX) Gets Price Target Boost from Guggenhe - GuruFocus
CTMX: Key Managers in Recent Offering - GuruFocus
Barclays raises its price target on CytomX Therapeutics, Inc. (CTMX) to $10 and maintains an overweight rating - MSN
CytomX Therapeutics (NASDAQ:CTMX) Sees Strong Trading Volume Following Analyst Upgrade - MarketBeat
CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price (CTMX) - Seeking Alpha
CytomX Therapeutics (NASDAQ:CTMX) Price Target Raised to $15.00 at Guggenheim - MarketBeat
CytomX Therapeutics prices $250M public offering at $5.30 per share - MSN
HC Wainwright Has Bearish Estimate for CTMX Q1 Earnings - MarketBeat
CytomX Therapeutics Prices $250 Million Securities Offering; Shares Up Pre-Bell - marketscreener.com
CytomX prices $250M stock offering at $5.30 per share By Investing.com - Investing.com South Africa
CytomX Therapeutics Confronts Rising AI Regulatory Risks and Cost Pressures - The Globe and Mail
Biotech CytomX prices $250M stock sale to fund Varseta-M - Stock Titan
CytomX Therapeutics (CTMX) Launches $250 Million Public Offering - GuruFocus
CTMX Analyst Rating Update: Wedbush Raises Price Target by 83% | - GuruFocus
CytomX Therapeutics prices public offering of 45,990,567 shares at $5.30 per share - marketscreener.com
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants - Bitget
CytomX Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock - Quiver Quantitative
Cytomx’s expanded readout supports late-stage testing of masked EpCAM ADC - biocentury.com
CytomX Therapeutics: Still Some Ways To Go (NASDAQ:CTMX) - Seeking Alpha
CytomX’s $250M Stock Offering: Boost for Varseta-M Development - StocksToTrade
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data - The Globe and Mail
CytomX Therapeutics (NASDAQ:CTMX) Trading Down 4.2% on Disappointing Earnings - MarketBeat
CytomX Therapeutics price target raised to $11 from $6 at Wedbush - TipRanks
CytomX Therapeutics (NASDAQ:CTMX) Given New $11.00 Price Target at Wedbush - MarketBeat
A Look At CytomX Therapeutics (CTMX) Valuation After Varseta M Phase 1 Expansion Data And Earnings Update - simplywall.st
Astellas Divorces CytomX Despite Positive Phase 1 Data for Antibody Platform - BioSpace
HighVista Strategies LLC Invests $820,000 in CytomX Therapeutics, Inc. $CTMX - MarketBeat
CTMX: JP Morgan Upgrades CytomX Therapeutics to Overweight, Rais - GuruFocus
CytomX Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:CTMX) 2026-03-17 - Seeking Alpha
Boothbay Fund Management LLC Buys Shares of 1,237,057 CytomX Therapeutics, Inc. $CTMX - MarketBeat
CytomX Launches $250 Million Stock Offering to Fund Cancer Drug Development - Intellectia AI
CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls - Stocktwits
CytomX Therapeutics (CTMX) Launches $250M Public Offering Amid E - GuruFocus
CytomX March 2026 slides: Varseta-M efficacy exceeds standard of care By Investing.com - Investing.com India
CytomX launches $250M public offering to fund drug development By Investing.com - Investing.com India
Oppenheimer Maintains Outperform on CytomX Therapeutics (CTMX) March 2026 - Meyka
CytomX reports phase 1 data for colorectal cancer drug candidate By Investing.com - Investing.com India
CytomX March 2026 slides: Varseta-M efficacy exceeds standard of care - Investing.com Canada
Decoding CytomX Therapeutics Inc (CTMX): A Strategic SWOT Insight - GuruFocus
CytomX Therapeutics Inc earnings missed by $0.24, revenue fell short of estimates - Investing.com Nigeria
Wedbush Remains a Buy on CytomX Therapeutics (CTMX) - The Globe and Mail
1.20%
0.06%
자본화:
|
볼륨(24시간):